Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine

← catalyst calendar

NCT06703190

Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With CVS Caremark.

Phase
Status
Terminated
Study type
Observational
Enrollment
1actual
Sites
1
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

This secondary data analysis of symptomatic CVS MinuteClinics patients testing for SARS-CoV-2 was terminated due to incomplete data on KP.2 vaccination status (exposure). Termination was not based on any safety concerns or regulatory requirements.

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-11-25actualWhen the study began enrolling
Primary completion2025-06-06actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-06-06actualThe whole study's end, after follow-up
First posted2024-11-25actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-11-06actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • COVID-19

Interventions

  • Biological: Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated — also filed as Exposed
  • Biological: Not vaccinated with 2024-2025 formulated COVID-19 vaccine — also filed as Unexposed

Primary outcomes

what the primary-completion date above is the date OF
Number of Pfizer/BioNTech 2024-2025 formulation vaccinated patients who test positive for SARS-CoV-2 ≥14 days after receipt of vaccine
measured September 2024 - April 2025
Number of COVID-19 2024-2025 formulation unvaccinated patients who test positive for SARS-CoV-2
measured September 2024 - April 2025
Number of Pfizer/BioNTech 2024-2025 formulation vaccinated patients who test negative for SARS-CoV-2 ≥14 days after receipt of vaccine
measured September 2024 - April 2025
Number of COVID-19 2024-2025 formulation unvaccinated patients who test negative for SARS-CoV-2
measured September 2024 - April 2025

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed